AKR1C3 and colorectal carcinoma: In addition, AKR1C1 and AKR1C3/17βHSD5 associate with cisplatin resistance in CRC, hence inhibitors of these AKR1Cs may be used to re-sensitize patients to chemotherapy (Matsunaga et al., 2013).